heart failure with reduced ejection fraction
Cardiovascular · 2016–2025
5decisions
4medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eplerenone Chronic heart failure with reduced ejection fraction (LVEF ≤40%), either within 3-14 days of acute myocardial infarction or symptomatic NYHA Class II, III, or… | Jul 2025 | Recommended with restriction | input received |
| dapagliflozin Treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in patients receiving concomitant optimal standard chronic heart failure… | Jul 2021 | Deferred | input received Diabetes Australia |
| dapagliflozin Treatment of patients with symptomatic chronic heart failure with reduced ejection fraction (NYHA class II-IV, LVEF ≤40%) receiving standard care comprising an… | Nov 2020 | Not recommended | none received |
| sacubitril/valsartan Extension to existing listing for chronic heart failure with reduced ejection fraction (LVEF <50%), allowing initiation without prior ACE inhibitor/ARB… | Nov 2020 | Not recommended | none received |
| sacubitril with valsartan Treatment of chronic heart failure with reduced ejection fraction (NYHA classes II-IV) with left ventricular ejection fraction ≤40%. | Mar 2016 | Not recommended | none received |
Who spoke
Diabetes Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.